Inozyme Pharma (INZY)
(Real Time Quote from BATS)
$4.59 USD
-0.01 (-0.22%)
Updated Jul 9, 2024 02:26 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
INZY 4.59 -0.01(-0.22%)
Will INZY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INZY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INZY
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Why Earnings Season Could Be Great for Inozyme (INZY)
INZY: What are Zacks experts saying now?
Zacks Private Portfolio Services
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
Other News for INZY
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
INZY Makes Bullish Cross Above Critical Moving Average
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
Inozyme initiated with bullish view at Wells Fargo, here's why